# IMMUNO-XAI Biological Interpretation

## Computational Analysis

- **Pipeline:** IMMUNO-XAI
- **Input cells:** 913
- **LLM:** groq/compound-mini

---

**# 1. Overall Finding**  
- The computational pipeline assigned immune‑state labels to 913 cells.  
- **Insufficient‑Evidence** dominates the annotation (≈ 95 % of cells).  
- Small minority fractions were labeled **Immune‑Excluded** (≈ 3.5 %) and **Immune‑Suppressed** (≈ 1.6 %). One cell was labeled **Myeloid‑Dominant**.  
- Mean confidence is high for the two minority states (1.0 for Immune‑Excluded, ≈ 0.78 for Immune‑Suppressed) but zero for the overwhelming Insufficient‑Evidence class.  

**# 2. Immune‑State Interpretation**  

| State | Cell count | Fraction | Mean confidence |
|-------|------------|----------|-----------------|
| Insufficient‑Evidence | 865 | 0.947 | 0.0 |
| Immune‑Excluded | 32 | 0.035 | 1.0 |
| Immune‑Suppressed | 15 | 0.016 | 0.78 |
| Myeloid‑Dominant | 1 | 0.001 | 0.26 |

- **Detected immune states:** The analysis reliably identifies a modest number of Immune‑Excluded and Immune‑Suppressed cells; the rest are classified as lacking sufficient evidence to make a confident call.  
- **Relative abundance:** The minority states together represent < 5 % of the total population.  
- **Confidence:** High confidence is reported only for the minority states; the bulk of cells have zero confidence, reflecting the algorithm’s inability to resolve their immune phenotype.  
- **Insufficient‑Evidence significance:** This category indicates that the transcriptomic signatures did not meet the predefined thresholds for any defined immune state. Consequently, the dataset provides **limited evidence** for robust immune‑state characterization.  

**# 3. Cluster‑Level Interpretation**  
- Ten clusters (0‑9) were identified. Every cluster is dominated (> 90 %) by the Insufficient‑Evidence label.  
- Clusters 1, 2, 3, 4, 7, and 9 contain small numbers of Immune‑Excluded (3‑10 cells) and/or Immune‑Suppressed (1‑6 cells).  
- Cluster 2 uniquely contains the single Myeloid‑Dominant cell.  
- Because the dominant label in each cluster is Insufficient‑Evidence, **no strong biological pattern can be inferred** from cluster composition beyond the sparse presence of the minority states.  

**# 4. Immune‑Signal Interpretation**  
| Score | Mean | Median | Std | Max |
|-------|------|--------|-----|-----|
| T‑cell activity | 0.0007 | 0.0 | 0.0218 | 0.658 |
| Cytotoxic activity | 0.0 | 0.0 | 0.0 | 0.0 |
| Myeloid signal | 0.0067 | 0.0 | 0.0288 | 0.295 |
| Immune suppression | 0.0053 | 0.0 | 0.0338 | 0.478 |
| Inflammatory signal | 0.0114 | 0.0 | 0.0749 | 1.393 |
| Antigen presentation | 0.0407 | 0.0 | 0.0665 | 0.413 |

- The **median** of every score is zero, indicating that the majority of cells have negligible measured activity for these immune functions.  
- **Maximum values** show that a few cells exhibit relatively higher signals (e.g., T‑cell activity up to 0.66, inflammatory signal up to 1.39), which likely correspond to the minority Immune‑Excluded or Immune‑Suppressed cells.  
- Overall, the data suggest **low global immune activity**, with only isolated cells showing modest signal intensity.  

**# 5. Pathway Interpretation**  
- All pathway scores have means near zero and large standard deviations, reflecting heterogeneous and weakly defined activity across cells.  
- Median values are close to zero (glycolysis ≈ ‑0.0065, oxidative phosphorylation ≈ 0.07, fatty‑acid metabolism ≈ 0.011, interferon response ≈ ‑0.073, inflammatory signaling ≈ ‑0.243, chemokine activity ≈ ‑0.094).  
- No pathway shows a consistent directional shift; therefore, **no definitive metabolic or inflammatory pathway activation can be claimed** from this dataset.  

**# 6. Machine‑Learning Interpretation**  
- **Prediction count:** 912 cells (one cell omitted from the ML step).  
- **Class distribution:** 869 Insufficient‑Evidence, 31 Immune‑Excluded, 12 Immune‑Suppressed.  
- The model is trained on a **highly imbalanced** dataset; the majority class overwhelms the minority classes.  
- Because only class counts are provided (no accuracy, balanced accuracy, or per‑class metrics), we cannot assess performance quantitatively.  
- Given the imbalance and the low number of minority‑class predictions, **any conclusions about the model’s ability to discriminate Immune‑Excluded or Immune‑Suppressed cells should be treated cautiously**.  

**# 7. XAI Interpretation**  
- SHAP analysis (200 cells explained) ranks features by mean absolute SHAP value.  
- Top contributors:  
  1. **immune_myeloid_signal** (0.125)  
  2. **immune_immune_suppression** (0.118)  
  3. **immune_antigen_presentation** (0.024)  
  4. Principal components (PC1, PC36, PC39, …).  
- These values indicate that, for the subset of cells examined, the myeloid and immune‑suppression scores most strongly **influence the model’s predictions**.  
- **Caution:** High SHAP importance reflects statistical contribution to the classifier, **not** a mechanistic or causal role of the underlying biology.  

**# 8. Integrated Biological Interpretation**  
- The dataset contains a large proportion of cells for which the algorithm cannot assign a confident immune state, limiting the ability to draw robust biological conclusions.  
- Within the small minority of cells labeled Immune‑Excluded or Immune‑Suppressed, modest elevations in myeloid and immune‑suppression scores are observed, and these same features are highlighted by SHAP as influential for the classifier.  
- No consistent activation of T‑cell, cytotoxic, or specific metabolic pathways is evident across the population.  
- Consequently, the integrated evidence points to **only sparse, low‑level myeloid‑related and immune‑suppressive signals in a minority of cells**, with the majority of the transcriptomic landscape remaining unresolved.  

**# 9. Limitations**  
1. **Insufficient‑Evidence dominance** (≈ 95 % of cells) indicates that the transcriptomic signatures did not meet criteria for any defined immune state.  
2. **Low confidence** for the majority class prevents reliable interpretation of those cells.  
3. **Class imbalance** in the ML model (869 vs. 31 vs. 12) likely biases predictions toward the majority label and reduces reliability for minority classes.  
4. **No performance metrics** (accuracy, balanced accuracy, recall) are supplied; thus, model quality cannot be quantified.  
5. **Pathway scores** have high variability and near‑zero means, precluding definitive pathway activation claims.  
6. **SHAP explanations** are limited to 200 cells and reflect model contribution, not biological causation.  
7. **Sample size of minority states** is small (≤ 32 cells), limiting statistical power.  

**# 10. Final Conclusion**  
The analysis reveals that, in this 913‑cell dataset, immune‑state assignment is largely indeterminate, with only a small subset of cells showing modest myeloid and immune‑suppressive signals; overall, the evidence for distinct immune activation or pathway engagement is limited.

**## One‑Line Conclusion**  
The data provide limited support for any robust immune‑state or pathway activity, with only sparse myeloid‑related signals detected in a minority of cells.

---

## Interpretation Disclaimer

This report interprets computational single-cell RNA-seq
analysis results. It does not establish causality, clinical
diagnosis, treatment response, or experimental validation.
